Pacer Advisors Inc. Has $258.41 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Pacer Advisors Inc. lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,040,742 shares of the biopharmaceutical company’s stock after selling 8,330 shares during the quarter. Bristol-Myers Squibb comprises about 1.0% of Pacer Advisors Inc.’s investment portfolio, making the stock its 23rd largest position. Pacer Advisors Inc. owned approximately 0.19% of Bristol-Myers Squibb worth $258,405,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Security Asset Management lifted its stake in shares of Bristol-Myers Squibb by 20.3% during the first quarter. Security Asset Management now owns 9,230 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 1,558 shares during the period. Richard P Slaughter Associates Inc lifted its stake in Bristol-Myers Squibb by 3.5% in the second quarter. Richard P Slaughter Associates Inc now owns 22,040 shares of the biopharmaceutical company’s stock valued at $1,409,000 after buying an additional 750 shares during the period. Talbot Financial LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $4,482,000. Ethic Inc. lifted its stake in Bristol-Myers Squibb by 26.4% in the first quarter. Ethic Inc. now owns 121,524 shares of the biopharmaceutical company’s stock valued at $8,423,000 after buying an additional 25,385 shares during the period. Finally, Atlas Wealth LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $276,000. Institutional investors and hedge funds own 74.98% of the company’s stock.

Insider Activity

In other news, EVP Robert M. Plenge sold 732 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the transaction, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now owns 27,868 shares in the company, valued at approximately $1,706,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert M. Plenge sold 732 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the sale, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BMY shares. Truist Financial reissued a “buy” rating and issued a $84.00 target price on shares of Bristol-Myers Squibb in a research note on Friday. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 1st. Credit Suisse Group dropped their price target on Bristol-Myers Squibb from $72.00 to $66.00 in a research report on Wednesday, July 12th. HSBC assumed coverage on Bristol-Myers Squibb in a research report on Friday, July 14th. They set a “reduce” rating and a $56.00 price target on the stock. Finally, Morgan Stanley reiterated an “underweight” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $70.67.

Bristol-Myers Squibb Price Performance

NYSE BMY traded down $0.20 during midday trading on Tuesday, hitting $58.38. The company had a trading volume of 2,506,812 shares, compared to its average volume of 8,964,190. The company has a market capitalization of $121.96 billion, a PE ratio of 15.58, a P/E/G ratio of 1.57 and a beta of 0.42. The company has a current ratio of 1.39, a quick ratio of 1.28 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $61.62 and a 200-day moving average price of $65.11. Bristol-Myers Squibb has a twelve month low of $58.33 and a twelve month high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing the consensus estimate of $1.99 by ($0.24). The company had revenue of $11.23 billion during the quarter, compared to analyst estimates of $11.81 billion. Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. Bristol-Myers Squibb’s revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.93 earnings per share. As a group, analysts anticipate that Bristol-Myers Squibb will post 7.44 earnings per share for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.